Epistra Inc. (Tokyo) has jointly developed a novel method with the Center for iPS Cell Research and Application (CiRA) at Kyoto University that combines cell image analysis and machine learning. This method enables early, non-destructive prediction of differentiation efficiency from human iPSCs to muscle stem cells (MuSCs). The research findings were published online in Scientific Reports on July 23, 2025.
Overview and Results
Human iPSCs have the ability to differentiate into various cell types and hold promise for applications in regenerative medicine and drug discovery. The “stepwise differentiation induction method” is advantageous in terms of safety due to its high maturity, but variability in efficiency and extended culture periods (several months) remain challenges.
In this joint research, MuSC differentiation induction was used as a model system. By combining image analysis and machine learning, a method was developed to predict final differentiation efficiency early and non-destructively. While MuSC differentiation typically requires approximately 80 days, this method can predict efficiency at days 24-34, potentially contributing to efficient cell acquisition and accelerating regenerative medicine research.
Key advantages include avoiding destructive analytical methods, eliminating subjective expert evaluation, and enabling rapid and objective determination of differentiation status using images alone.
Paper Information
- Journal: Scientific Reports
- DOI: 10.1038/s41598-025-11108-5
Related Articles
- Epistra Contributes Article on "AI-Robot-Driven Drug Development" to Pharmacia, Journal of the Pharmaceutical Society of JapanEpistra CTO Taku Tsuzuki and CEO Yosuke Ozawa contributed an article on AI-robot-driven drug development to Pharmacia, Vol. 62 No. 7, published by the Pharmaceutical Society of Japan.
- Cell Culture Optimization Software 'CellTune Ver.2' Launches GloballyEpistra Inc. announces the global launch of 'CellTune Ver.2,' the updated version of the co-developed cell culture optimization software with Shimadzu Corporation, on June 29, 2026. The new version introduces cloud-based subscription delivery and overseas expansion of custom media manufacturing services.
- Speaking Engagement: CEO Yosuke Ozawa Presented at the 10th Shonan iPark Regenerative Medicine SeminarOn June 3, 2026, Epistra Inc. CEO Yosuke Ozawa presented at the 10th Shonan iPark Regenerative Medicine Seminar, sharing implementation case studies and future prospects for AI and mathematical optimization in regenerative medicine process development.